NSCLC |
Non-small cell lung cancer |
RTK |
Receptor tyrosine kinase |
RAS |
Rat sarcoma virus |
RAF |
Serine/threonine-protein kinase |
KRAS |
Kirsten rat sarcoma |
EGFR |
Epidermal growth factor receptor |
BRAF |
v-Raf murine sarcoma viral oncogene homolog B |
MET |
Mesenchymal-epithelial transition |
PI3K |
Phosphoinositide 3-kinase |
HGF |
Hepatocyte growth factor |
MAPK |
Mitogen-activated protein kinase |
FISH |
Fluorescent in-situ hybridization |
TKI |
Tyrosine-kinase inhibitors |
PFS |
Progression-free survival |
OS |
Overall survival |
ORR |
Overall response rate |
HR |
Hazard ratio |
CI |
Confidence interval |
IV |
Intravenous |
IHC |
Immunohistochemistry |
DCR |
Disease control rate |
DOR |
Duration of response |
CNS |
Central nervous system |